THIS WEBSITE USES COOKIES
We use cookies to personalise content, to provide social media features, and to analyse our traffic. By choosing 'allow all cookies', you consent to our cookies.
To find out more, read our privacy policy and cookie policy.

Search
Close this search box.
Abbreviations

Abbreviations

GMB

Adult glioblastoma

pHGG

Paediatric high-grade glioma

UNCAN

EU initiative for understanding cancer

MRI

Magnetic resonance imaging 

SOC

Standard of care

I/O

Immuno-oncology

TTF

Tumour treating fields

CLINICAL TRIALS

How is the GLIOMATCH clinical study organised?

The clinical study is based on both retrospective and prospective data. The critical patient samples and data is collected across eight clinical centres specialising in neuro-oncological care for adults and children, with expertise in innovative immunotherapy treatments for GBM and pHGG. The aim of the clinical trials is to ensure significant impact on patient care within the participating countries and to developed tools which will be shared with the broader neuro-surgical and neuro-oncological community. 

Clinical trials glossary

Clinical trials glossary

Dendritic Cell Vaccine Trials (DC Vax)

A type of trials involving the testing of immunotherapeutic cancer vaccines, specifically dendritic cell vaccines, as a potential treatment for brain cancer.

Oncolytic Virus Immunotherapy Trials (OVIT)

Trials focused on evaluating oncolytic viruses as a form of immunotherapy for brain cancer, leveraging viruses to target and destroy cancer cells.

Monocentric Trials

Clinical trials conducted at a single research centre or site, often involving a specific institution or hospital.

Investigator-Initiated Single Site Trials

Clinical trials initiated and conducted by a specific researcher or group of researchers at a single location, typically with a primary investigator leading the study.

Retrospective Data

Involves the analysis of historical patient information and outcomes, often collected from medical records or databases.

Prospective Data

Information collected in real-time or planned in advance, typically focusing on future patient outcomes and treatment responses.

Patient stratification

The process of categorising individuals with similar characteristics or medical conditions into distinct groups to tailor specific and targeted healthcare interventions.

GLIOMATCH clinical partners

Retrospective data only

Structure

Text

Retrospective & Prospective data

Structure

Text

Prospective clinical trials

For the prospective trials, a small number of patients, between 6 and 25, is recruited over a 20 month period amongst the patients diagnosed with GBM and treated in the neurosurgery departments of the participating centres. Patients eligible for study entry are invited to take part in it and provided further information by the respective partner. The five prospective clinical trials (four DC Vax trials, one OVIT trial) take into account the overall aim of GLIOMATCH, the stratification of GBM patients according to distinct signatures, with the signatures not only identifying patients, who might benefit from immunotherapy, but also the probably most beneficial immunotherapeutic approach(es), while at the same time tackling different factors, which have been identified to probably affect efficacy of DC Vax and OVIT. All trials are investigator-initiated single site trials and all partners are large academic neurosurgical/neurooncological centres that treat high numbers of GBM patients yearly and have ample experience in running DC Vax or OVIT trials. The trials will be monocentric and conducted at the respective partners institution only.

Data collection

The GLIOMATCH clinical trials will analyse the largest cohort of I/O  treated GBM/pHGG patients (n>300, including pre-post treatment samples) with matched controls (n>300) and exceptionally long-term surviving GBM patients (n~140), in which various tumour-host niches will be studied in how they respond to immune-oncology perturbations and lead to improved clinical outcome. 25 years worth of data from retrospective trials will be used as input for the model. This includes over 300 immune-oncology treated GBM/pHGG patients with 300 matched controls, a cohort of ~90 TTF treated patients, and a cohort of more than 140 exceptionally long-term surviving patients to match the observed tumour-host profiles to therapy responsiveness. An additional ~50 patients will be recruited throughout the project for the study’s validation phase.